CL2011003097A1 - Compuestos derivados fluorados de amino-triazol, agonistas del receptor alx; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias, enfermedades obstructivas de las vias respiratorias, trastornos cardiovasculares y otras. - Google Patents

Compuestos derivados fluorados de amino-triazol, agonistas del receptor alx; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias, enfermedades obstructivas de las vias respiratorias, trastornos cardiovasculares y otras.

Info

Publication number
CL2011003097A1
CL2011003097A1 CL2011003097A CL2011003097A CL2011003097A1 CL 2011003097 A1 CL2011003097 A1 CL 2011003097A1 CL 2011003097 A CL2011003097 A CL 2011003097A CL 2011003097 A CL2011003097 A CL 2011003097A CL 2011003097 A1 CL2011003097 A1 CL 2011003097A1
Authority
CL
Chile
Prior art keywords
compounds
preparation
treatment
pharmaceutical composition
diseases
Prior art date
Application number
CL2011003097A
Other languages
English (en)
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2011003097A1 publication Critical patent/CL2011003097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)

Abstract

DERIVADOS DE AMINO-TRIAZOL DE FORMULA (I). DONDE A, R1 YR2 SON COMO SE DEFINE EN LA MEMORIA DESCRIPTIVA Y PLIEGO DE REIVINDICACIONES, AGONISTAS DEL RECEPTOR ALJ(, COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE A UNO DE LOS COMPUESTOS; Y USO DE LOS COMPUESTOS EN LA PREPARACIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, ENFERMEDADES OBSTRUCTIVAS DE LAS VÍAS RESPIRATORIAS, TRASTORNOS CARDIOVASCULARES Y OTRAS.
CL2011003097A 2009-06-09 2011-12-07 Compuestos derivados fluorados de amino-triazol, agonistas del receptor alx; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias, enfermedades obstructivas de las vias respiratorias, trastornos cardiovasculares y otras. CL2011003097A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2009052445 2009-06-09

Publications (1)

Publication Number Publication Date
CL2011003097A1 true CL2011003097A1 (es) 2012-07-06

Family

ID=42371383

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003097A CL2011003097A1 (es) 2009-06-09 2011-12-07 Compuestos derivados fluorados de amino-triazol, agonistas del receptor alx; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias, enfermedades obstructivas de las vias respiratorias, trastornos cardiovasculares y otras.

Country Status (22)

Country Link
US (1) US8580831B2 (es)
EP (1) EP2440555B1 (es)
JP (2) JP5095035B2 (es)
KR (1) KR101444559B1 (es)
CN (1) CN102414207B (es)
AR (1) AR077032A1 (es)
AU (1) AU2010258334B2 (es)
BR (1) BRPI1010738A8 (es)
CA (1) CA2760588C (es)
CL (1) CL2011003097A1 (es)
ES (1) ES2587139T3 (es)
IL (1) IL216792A (es)
MA (1) MA33420B1 (es)
MX (1) MX342440B (es)
MY (1) MY161243A (es)
NZ (1) NZ597453A (es)
PL (1) PL2440555T3 (es)
RU (1) RU2544862C2 (es)
SG (1) SG175363A1 (es)
TW (1) TWI404717B (es)
WO (1) WO2010143116A1 (es)
ZA (1) ZA201200127B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
BRPI0821115A8 (pt) 2007-12-18 2017-12-26 Actelion Pharmaceuticals Ltd Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
DK2432760T3 (da) 2009-05-18 2013-09-08 Actelion Pharmaceuticals Ltd Brokoblede spiro [2.4]-heptanderivater som alx-receptor og/eller fprl2-agonister
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
CA2814826C (en) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
SI2649068T1 (sl) * 2010-12-07 2015-01-30 Actelion Pharmaceuticals Ltd. Derivati oksazolil-metiletra kot agonisti alx-receptorja
WO2012077051A1 (en) * 2010-12-07 2012-06-14 Actelion Pharmaceuticals Ltd Hydroxylated aminotriazole derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
WO2013171687A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
EA029899B1 (ru) 2012-06-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Производные бензимидазол-пролина
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
US10370451B2 (en) 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
EP3022188B1 (en) 2013-07-18 2017-06-07 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
DK3077391T3 (en) 2013-12-04 2018-10-22 Idorsia Pharmaceuticals Ltd USE OF BENZIMIDAZOLE PROLINE DERIVATIVES
JP2024521807A (ja) 2021-06-01 2024-06-04 アズキュリス カンパニー，リミテッド 新規オキサゾール誘導体、及びそれを含むアレルギー性疾患の予防又は治療用薬学的組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
EP1319657A4 (en) 2000-09-22 2005-03-02 Nihon Nohyaku Co Ltd N- (4-PYRAZOLYL AMIDE) DERIVATIVES, CHEMICALS FOR AGRICULTURAL AND HORTICULTURAL USE AND APPLICATIONS THEREOF
EP1492552A2 (en) 2002-04-03 2005-01-05 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
KR20060130064A (ko) 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
US7329652B2 (en) * 2004-09-17 2008-02-12 Vertex Pharamaceuticals Incorporated Diaminotriazole compounds useful as protein kinase inhibitors
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8026260B2 (en) 2005-11-03 2011-09-27 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors with aryl-pyrazolyl-motifs
WO2009025793A2 (en) 2007-08-21 2009-02-26 Senomyx, Inc. Human t2r bitterness receptors and uses thereof
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
BRPI0821115A8 (pt) 2007-12-18 2017-12-26 Actelion Pharmaceuticals Ltd Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
DK2432760T3 (da) 2009-05-18 2013-09-08 Actelion Pharmaceuticals Ltd Brokoblede spiro [2.4]-heptanderivater som alx-receptor og/eller fprl2-agonister
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists

Also Published As

Publication number Publication date
MX2011012739A (es) 2011-12-16
ES2587139T3 (es) 2016-10-20
AU2010258334A1 (en) 2012-02-02
TWI404717B (zh) 2013-08-11
JP5095035B2 (ja) 2012-12-12
NZ597453A (en) 2013-03-28
KR20120089380A (ko) 2012-08-09
RU2544862C2 (ru) 2015-03-20
JP5775496B2 (ja) 2015-09-09
CA2760588C (en) 2017-08-08
JP2012255002A (ja) 2012-12-27
KR101444559B1 (ko) 2014-09-26
CA2760588A1 (en) 2010-12-16
BRPI1010738A8 (pt) 2017-12-26
IL216792A (en) 2014-05-28
ZA201200127B (en) 2014-06-25
WO2010143116A1 (en) 2010-12-16
CN102414207B (zh) 2015-09-30
JP2012529491A (ja) 2012-11-22
IL216792A0 (en) 2012-02-29
SG175363A1 (en) 2011-12-29
CN102414207A (zh) 2012-04-11
US20120101138A1 (en) 2012-04-26
AU2010258334B2 (en) 2015-02-26
TW201102383A (en) 2011-01-16
BRPI1010738A2 (pt) 2016-03-15
PL2440555T3 (pl) 2016-11-30
EP2440555A1 (en) 2012-04-18
AR077032A1 (es) 2011-07-27
MY161243A (en) 2017-04-14
US8580831B2 (en) 2013-11-12
MA33420B1 (fr) 2012-07-03
EP2440555B1 (en) 2016-05-18
MX342440B (es) 2016-09-29

Similar Documents

Publication Publication Date Title
CL2011003097A1 (es) Compuestos derivados fluorados de amino-triazol, agonistas del receptor alx; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias, enfermedades obstructivas de las vias respiratorias, trastornos cardiovasculares y otras.
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CO6700831A2 (es) Derivados de pirazina como bloqueadores de enac
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2008001301A1 (es) Compuestos derivados de heterociclos de nitrogeno; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una condicion inflamatoria o alergica, tal como una enfermedad inflamatoria u obstructiva de las vias respiratorias mediada por el bloqueo del canal de sodio epitelial.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CR10335A (es) Compuestos organicos
DOP2011000218A (es) Derivados de sulfonamida
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
CR9504A (es) Imidazoquinolinas como inhibidores de cinasa de lipido
CL2011000425A1 (es) Compuestos derivados de heteroariloxi amidas del acido benzoico sustituido, inhibidores de map-quinasa p38; procedimiento de preparacion de los compuestos; composicion farmaceutica; procedimiento para preparar dicha composicion; y uso en el tratamiento de enfermedades de las vias aereas como epoc y asma.
CO6300957A2 (es) Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2009001248A1 (es) Compuestos derivados de indazolilo sustituido con fenilo, que actúan como moduladores de glucocorticoides; composición y combinación farmacéutica que comprenden a uno de los compuestos; y uso de los compuestos en la preparación de medicamentos para el tratamiento de enfermedades inflamatorias y respiratorias.
ECSP10010209A (es) Agonistas novedosos de los receptores de glucocorticoides
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
ECSP099063A (es) Derivados de purina como agonistas de a2a
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
UY31159A1 (es) Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos
UY33485A (es) Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos.
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)